Glaucoma Drug Latanoprostene Bunod Enters Trial Phase 3

Eye health company Bausch + Lomb, based in Rochester, N.Y., announced it had begun the third phase of testing for latanoprostene bunod, a drug it is licensing from Paris-based Nicox for experimental use in patients with glaucoma or ocular hypertension.

The drug, previously known as BOL-303259-X and NCX 116 is a nitric oxide-donating prostaglandin F2 alpha analog, for which Bausch paid the French company an initial $10 million in March 2010, according to a release. Results from Phase 2b testing in 2011 were positive, so Bausch paid Nicox another $10 million to pursue further testing in a Phase 3's two separate randomized, multicenter, double-masked, parallel-group studies, according to the release.

Nicox could earn as much as $162.5 million from Bausch if the product goes to market, and would receive tiered double-digit royalties from sales and be able to co-promote the product in the U.S.

More Articles on Ophthalmology:

50 Statistics on ASC Net Revenue by Specialty
10 Milestones for Ambulatory Surgery Centers
3 Reasons LASIK Surgery is More Popular in the Winter

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast